Novopor Advanced Science Private Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Novopor Advanced Science Private Limited - overview
Established
1994
Location
Hyderabad, Telangana, India
Primary Industry
Chemicals
About
Based in Telangana, India, and founded in 1994, Novopor Advanced Science Private Limited ,formerly known as Porus Laboratories Private Limited, operates as a chemical company that develops and manufactures agricultural and specialty chemicals, including APIs, spirapril, quinapril, and almotriptan intermediates. In June 2023, Bain Capital agreed to acquire Novopor Advanced Science Private Limited. The deal valued the company at INR 2. 4 billion.
As of June 2023, Srinivasan Namala is the CEO of the company. The company’s product line includes API's, sumatriptan intermediates, almotriptan intermediates, zolmitriptan intermediates, rizatriptan benzoate intermediates, naratriptan intermediates, frovatriptan intermediates, montelukast intermediates, quinapril intermediates, ondansetran intermediates, irbesartan intermediates, spirapril intermediates, sulpha drug intermediates, and more across various sectors, including specialty polymers, electronic chemicals, and agrochemicals. Novopor Advanced Science Private Limited plans to use its partnership with Bain Capital to support its growth and enhance its chemical capabilities.
Current Investors
Bain Capital
Primary Industry
Chemicals
Sub Industries
Agricultural Chemicals, Medicinal Chemicals & Botanicals
Website
www.poruslabs.com
Verticals
Manufacturing
Company Stage
Mature - Buyout
Total Amount Raised
Subscriber access only
Novopor Advanced Science Private Limited - timeline of key events
Novopor Advanced Science Private Limited - financials
| Fiscal Year Ended | Mar 31, 2014 | Mar 31, 2015 | Mar 31, 2016 | Mar 31, 2017 | Mar 31, 2018 | Mar 31, 2019 | Mar 31, 2020 | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 1,852,245,453 | 2,225,715,729 | 2,298,585,642 | 3,537,284,221 | 4,017,334,572 | 4,482,647,549 | 8,028,592,053 | 8,351,429,107 | - | - | - |
| % Revenue Growth (YoY) | - | 20.2% | 3.3% | 53.9% | 13.6% | 11.6% | 79.1% | 4.0% | - | - | - |
| EBITDA (USD) | 142,400,727 | 225,715,923 | 253,689,854 | 1,007,868,448 | 701,805,892 | 693,041,321 | 2,093,380,614 | 2,445,049,873 | - | - | - |
| Operating Income (USD) | 96,245,215 | 195,166,323 | 215,432,636 | 952,136,373 | 627,594,616 | 598,743,237 | 1,921,111,021 | 2,244,641,876 | - | - | - |
| Operating Margin | 5.2% | 8.8% | 9.4% | 26.9% | 15.6% | 13.4% | 23.9% | 26.9% | - | - | - |
| % EBITDA Margin | 7.7% | 10.1% | 11.0% | 28.5% | 17.5% | 15.5% | 26.1% | 29.3% | - | - | - |
| NET Income (USD) | 45,483,001 | 109,324,800 | 102,167,694 | 632,132,394 | 416,098,393 | 386,356,952 | 1,311,142,997 | 1,809,889,848 | - | - | - |
| % Net Margin | 2.5% | 4.9% | 4.4% | 17.9% | 10.4% | 8.6% | 16.3% | 21.7% | - | - | - |
Novopor Advanced Science Private Limited - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Trade Sale | Completed | Far Chemical, Inc. | - | ||||||||
| Add-on | Completed | Pressure Chemical Co. | - | ||||||||
| Buyout | Completed | Novopor Advanced Science Private Limited | - |
Displaying 1 - 3 of 3
Novopor Advanced Science Private Limited - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.